Drug Trial News

RSS

Adamas Pharmaceuticals presents study results of TCAD therapy in immunocompromised influenza A patients

Adamas Pharmaceuticals, Inc., a privately held company, announced today the results from the first clinical study evaluating triple combination antiviral drug (TCAD) therapy for the treatment of influenza A in immunocompromised patients. Data from this Phase 1b study were presented by clinical investigator Dr. Janet Englund in a clinical symposium at the 23rd International Conference on Antiviral Research (ICAR) in San Francisco.

29 Apr 2010

Celladon's first Phase II trial of MYDICAR for advanced heart failure meets primary endpoint

Targeted Genetics Corporation announced today that its licensing partner, Celladon Corporation, has reported today that Celladon's first Phase II trial with MYDICAR® for the treatment of advanced heart failure has met its primary safety and efficacy endpoints, as prospectively defined in the Phase II trial protocol.

29 Apr 2010

Ceregene continues enrollment in new Phase 1/2 clinical study of CERE-120 for Parkinson's disease

Ceregene, Inc., a biopharmaceutical company, announced today that enrollment is proceeding in a new Phase 1/2 clinical study evaluating CERE-120, a gene therapy product which delivers the neurotrophic factor neurturin, to dying neurons in Parkinson's disease patients. This new clinical study follows a completed Phase 2 trial and builds on experience gained in that trial, by enhancing the dosing regimen and optimizing the duration of patient follow up.

29 Apr 2010

Phase 1B/2 clinical study to evaluate efficacy of PMX-60056 in reversing heparin levels initiated

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has initiated a Phase 1B/2 dose-ranging clinical study with its anticoagulant reversing agent, PMX-60056. The study is intended to demonstrate the safety and efficacy of PMX-60056 in reversing varying heparin levels, including the highest levels commonly used in surgical settings.

29 Apr 2010

Positive results from interim analysis of ongoing Phase 2a study of BCX4208

BioCryst Pharmaceuticals, Inc. announced positive top-line results from a planned interim analysis of its ongoing Phase 2a, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of orally administered BCX4208 in patients with gout.

28 Apr 2010

Diamyd Medical to focus on completion of Diamyd Phase III studies and preparation for market launch

“Besides our ongoing partnership discussions, we will primarily focus on completing the Phase III studies and prepare for market launch of Diamyd®.”

28 Apr 2010

BiondVax announces successful conclusion of second Phase I/II trial of Multimeric-001 Universal Flu Vaccine

BiondVax Pharmaceuticals Ltd., an Israeli biopharmaceutical company at the forefront of global efforts towards the development of a Universal Influenza Vaccine, announced the successful conclusion of the Company's second Phase I/II clinical trial of the Multimeric-001 Universal Influenza Vaccine.

28 Apr 2010

Seattle Genetics reports revenues of $46.5M for first-quarter 2010

Seattle Genetics, Inc. today reported financial results for the first quarter ended March 31, 2010. The company also highlighted recent product development activities and planned milestones.

28 Apr 2010

Diamyd Medical reports group net sales of MSEK 0.2 for second-quarter 2010

Second quarter report for Diamyd Medical AB (publ), fiscal year 2009/2010

28 Apr 2010

Update on ICA-105665 clinical development plans for treatment of epilepsy and pain

Icagen, Inc. today provided an update on clinical development plans for ICA-105665, the Company's novel drug candidate for the treatment of epilepsy and pain.

28 Apr 2010

ChronSeal multi-center study in Sweden and Norway finalized

The multi-center study in Sweden and Norway with ChronSeal® is now finalized and the data are being analyzed in Sweden and by Kringle in Japan. ChronTech and Kringle have jointly decided that the results will be publicly available on May 27th. At follow-up of the ChronVac-C® -study where patients now have started treatment according to standard-of-care (interferon and ribavirin) all patients (100%) were virus free at treatment week 12 and 5/6 (83%) had less than 50 copies of virus/mL blood already at treatment week four.

28 Apr 2010

DARA Therapeutics collaborates to advance clinical study of KRN5500 for CIPN in cancer patients

DARA BioSciences, Inc. announced today that on April 26, 2010, DARA Therapeutics, a subsidiary of DARA BioSciences, and the Division of Cancer Prevention, National Cancer Institute (NCI), National Institutes of Health (NIH), entered into a Clinical Trials Agreement to advance the clinical study of KRN5500 for the treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN) in patients with cancer. Under the terms of the collaboration, NCI will fund the studies and DARA will supply KRN5500 and placebo.

28 Apr 2010

NCCTG to conduct Phase II study of brostallicin in combination with cisplatin for mTNBC cancer

Cell Therapeutics, Inc. today announced that the North Central Cancer Treatment Group ("NCCTG") plans to conduct a Phase II study of brostallicin in combination with cisplatin in patients with metastatic triple-negative breast ("mTNBC") cancer, defined by tumors lacking expression of estrogen, progesterone receptors and without over-expression of HER2. Additionally, the majority of breast cancers that are associated with the susceptibility mutation (BRCA1) are of the triple-negative type.

28 Apr 2010

Lexicon Pharmaceuticals to present Phase 2 study results of LX1031 for non-constipating IBS at DDW 2010

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that the company will be giving poster and oral presentations on results from its Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS) at Digestive Disease Week (DDW) 2010 in New Orleans, Louisiana.

28 Apr 2010

Phase II clinical trial to test safety and efficacy of transplanted encapsulated islets

The Juvenile Diabetes Research Foundation announced today that it is partnering with Living Cell Technologies, a New Zealand-based biotechnology company focused on developing cell based therapeutics, in a Phase II clinical trial to study the safety and effectiveness of transplanting encapsulated insulin-producing cells from pigs as a treatment for type 1 diabetes with significant hypoglycemia unawareness.

28 Apr 2010

Phase I clinical trial results of AE37 in prostate cancer patients presented at EAU Congress

Generex Biotechnology Corporation today announced presentation of additional results from a recently completed Phase I clinical trial of its novel immunotherapeutic peptide AE37 in prostate cancer patients. AE37 is a synthetic cancer vaccine being developed by Antigen Express, Inc., a wholly owned subsidiary of Generex, for multiple cancer indications.

28 Apr 2010

Debiopharm commences treatment in Phase I clinical trial for Debio 0932 small molecule Hsp90 inhibitor

Curis, Inc. announced today that its licensee Debiopharm S.A. has treated the first patient in a Phase I clinical trial for small molecule heat shock protein 90 (Hsp90) inhibitor Debio 0932, formerly called CUDC-305.

27 Apr 2010

Alnylam Pharmaceuticals publishes encouraging results from Phase II GEMINI study in PNAS

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has published results from its Phase II GEMINI study in the Proceedings of the National Academy of Sciences (PNAS). These data, previously presented at the International Symposium on Respiratory Viral Infections in Singapore in 2008, showed human proof of concept with an RNAi therapeutic in a randomized, double blind, placebo-controlled study.

27 Apr 2010

Interim results from Phase I clinical trial of PLX-PAD for treatment of CLI

Pluristem Therapeutics Inc. today announced interim top-line results from its Phase I clinical trials utilizing its placenta-derived cell therapy product, PLX-PAD, for the treatment of critical limb ischemia, the end-stage of peripheral artery disease. The interim data demonstrated that PLX-PAD is safe, well tolerated and effective.

27 Apr 2010

ViroPharma initiates multi-dose Phase 2 study of Cinryze in patients with HAE

ViroPharma Incorporated today announced that it has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous versus intravenous administration of Cinryze (C1 esterase inhibitor [human)] in 24 adolescents and adult subjects with hereditary angioedema.

27 Apr 2010

Drug Trial News

Adamas Pharmaceuticals presents study results of TCAD therapy in immunocompromised influenza A patients

Celladon's first Phase II trial of MYDICAR for advanced heart failure meets primary endpoint

Ceregene continues enrollment in new Phase 1/2 clinical study of CERE-120 for Parkinson's disease

Phase 1B/2 clinical study to evaluate efficacy of PMX-60056 in reversing heparin levels initiated

Positive results from interim analysis of ongoing Phase 2a study of BCX4208

Diamyd Medical to focus on completion of Diamyd Phase III studies and preparation for market launch

BiondVax announces successful conclusion of second Phase I/II trial of Multimeric-001 Universal Flu Vaccine

Seattle Genetics reports revenues of $46.5M for first-quarter 2010

Diamyd Medical reports group net sales of MSEK 0.2 for second-quarter 2010

Update on ICA-105665 clinical development plans for treatment of epilepsy and pain

ChronSeal multi-center study in Sweden and Norway finalized

DARA Therapeutics collaborates to advance clinical study of KRN5500 for CIPN in cancer patients

NCCTG to conduct Phase II study of brostallicin in combination with cisplatin for mTNBC cancer

Lexicon Pharmaceuticals to present Phase 2 study results of LX1031 for non-constipating IBS at DDW 2010

Phase II clinical trial to test safety and efficacy of transplanted encapsulated islets

Phase I clinical trial results of AE37 in prostate cancer patients presented at EAU Congress

Debiopharm commences treatment in Phase I clinical trial for Debio 0932 small molecule Hsp90 inhibitor

Alnylam Pharmaceuticals publishes encouraging results from Phase II GEMINI study in PNAS

Interim results from Phase I clinical trial of PLX-PAD for treatment of CLI

ViroPharma initiates multi-dose Phase 2 study of Cinryze in patients with HAE

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News